GLS and cancer: It is noteworthy that the inhibition of glutaminase by CB-839 as well as the addition of oxidants was found to decrease the endogenous glutamate content and to sensitize cancer cells to NEAA withdrawal, even in absence of alterations in the KEAP1/NRF2 pathway [111].